Rockville, Maryland, Aug. 10, 2009 – Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced the promotion of Mr. Rick Soni to President and Chief Operating Officer. In his new role, Mr. Soni will have full responsibility for creating business strategy, and executing the strategic and tactical operational plans for the company. His responsibilities will also include managing the full range of day-to-day operations while reporting directly to the CEO.
Mr. Soni joined Rexahn in 2008 as Chief Business Officer with over 25 years of marketing, business development and general management experience in the pharmaceutical industry. Prior to joining Rexahn, he held several leadership roles at Otsuka America Pharmaceuticals, Inc., with responsibility for commercial development, corporate strategy and execution of licensing and acquisition of therapeutics, diagnostics and medical devices. Previously, Mr. Soni had held a variety of management positions at Novartis and Schering-Plough. Mr. Soni has a BS from University of Wisconsin-Madison and an MBA from Fairleigh Dickinson University.
Dr. Chang Ahn, Rexahn’s Chairman and Chief Executive Officer, commented, “Since joining Rexahn in 2008, Rick has proven to be an effective leader and outstanding member of our management team. He has shown unparalleled dedication to advancing our company through the establishment of relationships with pharmaceutical firms, as well as building our base of key institutional investor relationships. I know that I speak for our entire company in congratulating Rick on his new position.”
